Paige AI
Cancer diagnosis is complex, but with Paige, it’s never been more precise. Our AI-powered solutions provide a deep understanding of cancer’s molecular and cellular complexities, helping to deliver reliable detection and characterization of disease. From tissue analysis to molecular profiling, we’re redefining what’s possible in precision diagnostics. Paige’s exclusive access to millions of digitized pathology slides, clinical reports, and genomic data sets us apart. By leveraging this data, we bring an enhanced understanding of cancer to patients, helping drive transformative breakthroughs in cancer diagnostics and care. AI that encompasses a broad spectrum of gender, race, ethnicity, and geographical regions 800+ laboratory and medical institutions Our mission is committed to enhancing the precision and impact of cancer diagnostics. Paige’s AI solutions is designed to equip healthcare professionals with tools needed to navigate the complexities of cancer to deliver informed care. To truly understand cancer, you need to start at its foundation—pathology. Paige’s groundbreaking approach begins here, combining advanced AI expertise with insights from world-renowned medical and scientific experts. Leveraging the largest, most diverse digital pathology dataset available, our technology delivers novel insights like never before. 25 million accessible pathology slides 200 thousand cases with outcome and genomic data Paige has gained recognition by leading news organizations and press By the industry’s most influential investors
Recursion
Dive into Recursion's innovative approach to decoding biology. Join our mission & explore what AI drug discovery companies can do. Contact us
Recursion was founded more than a decade ago on the idea that we could take images of cells and use these images to train artificial intelligence to understand the vast unknown biological space – the cellular disruptions driving disease – to use AI-drug discovery to reduce the massive 90% failure rate of traditional drug discovery. Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas Leveraging the Power of Patient Data in AI-Drug Discovery Will AI ever cure cancer? The multibillion-dollar race to bring the first AI-discovered drug to market
Paige AI
Recursion
Paige AI
Recursion
Recursion (1)
Only in Paige AI (4)
Only in Recursion (10)
Paige AI
Recursion
Paige AI
Recursion
